DENVER, April 20, 2017 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, announced today that it has reformulated and relaunched its popular Re-Con product. The new and improved Re-Con is available as part of the Company's Sports Series.
As one of the only sports nutrition companies with a scientific institute that tests ingredients and develops research in-house, as well as partners with prestigious universities and research institutions, MusclePharm reevaluates its products on an ongoing basis to ensure that it is using the best ingredients currently available. After extensive research, the Company has reformulated Re-Con to include Groplex(™) and VitaCherry(™) Sport. Currently, Re-Con is the only workout recovery product available that includes these ingredients.
- GroPlex, developed by Glanbia, a leading creator of ingredient solutions for the food, beverage and supplement industries, is a unique complex of dairy proteins and peptides that are high in protein but low in fat and carbohydrates. GroPlex has been shown to cause a release of the anabolic or muscle building hormone insulin, which can improve the delivery of nutrients to muscle and activates the muscle growth pathway (MTOR) for muscle synthesis.
- VitaCherry, developed in collaboration with Futureceuticals VDF, is a carefully processed whole tart cherry, which has traditionally been used by athletes for recovery and to promote reduction in muscle soreness. VitaCherry Sport is processed in a way that yields higher concentrations of the beneficial nutrients that prevent muscle soreness.
"As one of the only sports nutrition companies able and committed to conducting primary research, MusclePharm is uniquely positioned to validate the impact of the latest ingredients that support athletic performance and health," said Ryan Drexler, CEO and Chairman of the Board, "Over the past 18 months we undertook a review of some of our best-selling products – including Assault, Combat Protein and Shred – and made significant improvements. Re-Con is the latest example of this effort. As a result, I am confident that the thousands of retail outlets around the world, both brick and mortar and online, that carry MusclePharm products will add the newly formulated Re-Con to their line."
Re-Con was developed for use by all types of athletes – from professionals to weekend warriors. The product's benefits include: reduction of muscle soreness, repair of damaged muscles and replenishment of vital nutrients for the body post-workout.
About MusclePharm Corporation
MusclePharm® is a scientifically-driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. Its portfolio of recognized brands includes MusclePharm® Sport Series, Black Label and Core Series, FitMiss™, as well as Natural Series which was launched in 2017. These products are available in more than 120 countries and over 50,000 retail outlets worldwide. The clinically-proven supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit http://www.musclepharm.com. To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the Securities and Exchange Commission, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
SOURCE MusclePharm Corporation